This is in concordance with a few other reports which indicated that CYP1B1 4326 G allele was associated with a lower response rate, progressive free survival rate (PFS) and decreased overall survival in breast cancer patients treated with taxanes (Marsh et al., 2007). Here, CYP1B1 is linked to breast carcinoma.